Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 26
Filter
1.
Climacteric ; 19(4): 393-9, 2016 Aug.
Article in English | MEDLINE | ID: mdl-27338648

ABSTRACT

OBJECTIVE: The adaptation of the brain to aging is subject to the impact of psychological and environmental factors and possibly climacteric symptomatology. We aimed to determine the association of climacteric symptomatology with different aspects of episodic memory in a sample of Greek menopausal women. METHODS: This cross-sectional study included 39 postmenopausal women with subjective memory complaints. Memory performance was evaluated using the Hopkins Verbal Learning Test (HVLT) and the revised Brief Visuospatial Memory Test (BVMT), assessing verbal and visuospatial episodic memory, respectively. We evaluated general cognitive status using the Mini-Mental State Examination (MMSE) and the Clock Drawing Test. Menopausal symptoms were assessed using Greene's Climacteric scale. RESULTS: In the multivariate approach, vasomotor symptoms predicted independently HVLT (retained percentage and delayed recall: b-coefficient = -0.568, p = 0.009 and b-coefficient = -0.563, p = 0.012, respectively). Psychological symptoms predicted independently MMSE (b-coefficient = -0.391, p = 0.024); and in combination with free estrogens (logFEI), psychological symptoms predicted BVMT (total and delayed recall: b-coefficient = -0.558, p = 0.001 and b-coefficient = -0.474, p = 0.005) and HVLT discrimination index (b-coefficient = -0.390, p = 0.023). Combined symptomatology predicted independently MMSE (b-coefficient = -0.457, p = 0.006) and HVLT total (b-coefficient = -0.557, p = 0.034); combined symptomatology predicted in combination with logFEI scores of BVMT total (b-coefficient = -0.593, p < 0.001), BVMT delayed recall (b-coefficient = -0.492, p = 0.002). CONCLUSION: The intensity of psychological, vasomotor and combined climacteric symptoms predicted cognitive performance in this sample of postmenopausal women. A differential contribution of vasomotor symptoms to episodic memory is described, with the negative impact being more pronounced in visuospatial rather than verbal episodic memory.


Subject(s)
Aging/psychology , Memory Disorders/physiopathology , Memory, Episodic , Postmenopause/physiology , Postmenopause/psychology , Adult , Aged , Cross-Sectional Studies , Female , Greece , Humans , Middle Aged , Neuropsychological Tests , Pilot Projects , Verbal Learning
2.
Clin Nucl Med ; 41(3): 194-200, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26673241

ABSTRACT

AIM: In patients with progressive, metastatic neuroendocrine tumors (NET), intra-arterial radionuclide infusions with high activities of In-[DTPA]-octreotide and more recently with non-carrier added (nca) Lu-[DOTA,Tyr]-octreotate have been performed with encouraging results. However, the affinity profiles (IC50) of these radiopeptides for human sst2 receptors are markedly different (In-[DTPA]-octreotide, 22 ± 3.6 nM and nca Lu-[DOTA,Tyr]-octreotate, 1.5 ± 4.0 nM). The total administered activity is determined by organ dose limits (kidneys and bone marrow), and our aim therefore was to compare and evaluate the therapeutic efficacy of both radiopeptides in metastatic NETs. METHODS: Thirty patients with gastroenteropancreatic (GEP) somatostatin-positive NETs with liver metastases confirmed on biopsy and In-pentetreotide scan were included. They were treated with In-[DTPA]-octreotide (n = 17) or nca Lu-[DOTA,Tyr]-octreotate (n = 13). Blood samples were collected 2, 4, 8, and 24 hours postadministration to calculate residence time in blood and in red marrow. The maximum percentage uptake in organs and tumors was estimated by region of interest analysis, and tumor dosimetry calculations were performed using OLINDA/EXM/ 1.0 software. RESULTS: ncaLu-[DOTA,Tyr3]-octreotate blood radioactivity, expressed as a percentage of the injected dose, was significantly lower than In-[DTPA]-octreotide (P < 0.05), as clearly depicted from the time-activity curves; the background-corrected tumor uptake was significantly higher than In-[DTPA]-octreotide but without any significant difference in other organs (spleen, kidneys, and liver). CONCLUSIONS: Using Lu-[DOTA,Tyr]-octreotate, a 3-fold higher absorbed dose to tumor tissue was achieved compared with In-[DTPA] octreotide. Residence time of nca Lu-[DOTA,Tyr]-octreotate results in a significantly higher absorbed dose to bone marrow compared with In-[DTPA]-octreotide. However, a drawback of In-[DTPA]-octreotide therapy is that the number of administrations would need to be almost doubled to achieve an equal therapeutic outcome as compared with Lu-[DOTA,Tyr]-octreotate.


Subject(s)
Liver Neoplasms/radiotherapy , Neuroendocrine Tumors/drug therapy , Octreotide/analogs & derivatives , Pentetic Acid/analogs & derivatives , Radiopharmaceuticals/therapeutic use , Adult , Aged , Female , Humans , Liver Neoplasms/secondary , Male , Neuroendocrine Tumors/pathology , Octreotide/administration & dosage , Octreotide/adverse effects , Octreotide/therapeutic use , Pentetic Acid/administration & dosage , Pentetic Acid/adverse effects , Pentetic Acid/therapeutic use , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/adverse effects
4.
Eur J Neurol ; 18(1): 93-8, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20500803

ABSTRACT

BACKGROUND: utilization of antiepileptic drugs (AEDs) has long been associated with bone deleterious effects. Furthermore, the BsmI restriction fragment polymorphism of the vitamin D receptor (VDR) has been associated with reduced bone mineral density (BMD), mostly in postmenopausal women. This study evaluates the association between bone metabolism of patients with epilepsy and the BsmI VDR's polymorphism in chronic users of AEDs. METHODS: this study evaluated 73 long-term users of antiepileptic drug monotherapy, in a cross-sectional design. Fasting blood samples were obtained to estimate the circulating serum levels of calcium, magnesium, phosphorus, parathormone, 25 hydroxyvitamin D as well as the VDR's genotype. Bone mineral density at the lumbar spine was measured with Dual Energy X-Ray Absorptiometry. RESULTS: bone mineral density was significantly associated with the genotype of VDR (mean BMD: Bb genotype 1.056 ± 0.126 g/cm(2) ; BB genotype 1.059 ± 0.113 g/cm(2) ; bb genotype 1.179 ± 0.120 g/cm(2) ; P < 0.05). Additionally, the presence of at least one B allele was significantly associated with lower bone mineral density (B allele present: BMD = 1.057 ± 0.12 g/cm(2) , B allele absent: BMD = 1.179 ± 0.119 g/cm(2) ; P < 0.01). Patients with at least one B allele had lower serum levels of 25 hydroxyvitamin D when compared with bb patients (22.61 ng/ml vs. 33.27 ng/ml, P < 0.05), whilst they tended to have higher levels of parathyroid hormone. DISCUSSION: vitamin D receptor polymorphism is associated with lower bone mass in patients with epilepsy. This effect might be mediated through the vitamin D-parathormone pathway.


Subject(s)
Anticonvulsants/therapeutic use , Bone Density/genetics , Epilepsy/drug therapy , Epilepsy/genetics , Receptors, Calcitriol/genetics , Absorptiometry, Photon , Adolescent , Adult , Alleles , Calcium, Dietary , Carbamazepine/analogs & derivatives , Carbamazepine/therapeutic use , Cross-Sectional Studies , Female , Genotype , Humans , Levetiracetam , Male , Middle Aged , Oxcarbazepine , Piracetam/analogs & derivatives , Piracetam/therapeutic use , Polymorphism, Genetic , Premenopause/genetics , Regression Analysis , Statistics, Nonparametric , Valproic Acid/therapeutic use
5.
Int J Neurosci ; 118(9): 1251-7, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18698508

ABSTRACT

Aim of the report was the study of the clinical features of neurosyphilis in the last 40 years (1965-2005). The investigation was based on the retrospective review of patients with neurosyphilis hospitalized in our hospital from 1965 to 2005 (period A: 1965-1984 and B: 1985-2005). Eighty one patients with neurosyphilis were studied. Typical forms represent 68.6% of cases of neurosyphilis in period A. In period B, 85.7% of the cases are presented with atypical clinical patterns. Typical forms of the disease were no longer common, while atypical and masked clinical patterns prevailed. Neuropsychiatric symptoms were the most common manifestations of the disease.


Subject(s)
Neurosyphilis/diagnosis , Neurosyphilis/epidemiology , Adult , Aged , Aged, 80 and over , Female , Humans , Incidence , Male , Middle Aged , Neurosyphilis/pathology , Retrospective Studies
6.
Mult Scler ; 14(2): 219-30, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17942521

ABSTRACT

This study aims to validate the Multiple Sclerosis (MS) International Quality of Life (MusiQoL) questionnaire, a multi-dimensional, self-administered questionnaire, available in 14 languages, as a disease-specific quality of life scale that can be applied internationally. A total of 1992 patients with different types and severities of MS from 15 countries were recruited. At baseline and day 21 +/- 7, each patient completed the MusiQoL, a symptom checklist and the short-form (SF)-36 QoL questionnaire. Neurologists also collected socio-demographic, MS history and outcome data. The database was randomly divided into two subgroups and analysed according to different patient characteristics. For each model, psychometric properties were tested and the number of items was reduced by various statistical methods. Construct validity, internal consistency, reproducibility and external consistency were also tested. Nine dimensions, explaining 71% of the total variance, were isolated. Internal consistency and reproducibility were satisfactory for all the dimensions. External validity testing revealed that dimension scores correlated significantly with all SF-36 scores, but showed discriminant validity by gender, socio-economic and health status. Significant correlations were found between activity in daily life scores and clinical indices. These results demonstrate the validity and reliability of the MusiQoL as an international scale to evaluate QoL in patients with MS.


Subject(s)
Multiple Sclerosis/psychology , Psychometrics/standards , Quality of Life , Surveys and Questionnaires/standards , Female , Global Health , Health Status , Humans , Male , Multiple Sclerosis/physiopathology , Reproducibility of Results , Sensitivity and Specificity
7.
Clin Neuropsychol ; 22(5): 842-50, 2008 Sep.
Article in English | MEDLINE | ID: mdl-17934999

ABSTRACT

The purpose of this study was to explore the effects of age and education on the performance of the Trail Making Test (TMT), and to provide normative data in the Greek population. The TMT was administered to 643 healthy participants. All participants satisfied the criteria excluding dementia and other medical, psychiatric, and neurological disorders. Statistical analysis revealed that, age, education, and general level of intelligence significantly influence individual performance. Performance on TMT, especially part B, decreases with increasing age and lower levels of education. Current norms of the Greek version of TMT represent a useful set of norms for clinical practice.


Subject(s)
Cognition/physiology , Psychomotor Performance/physiology , Trail Making Test/statistics & numerical data , White People/psychology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Aging/psychology , Analysis of Variance , Cultural Characteristics , Educational Status , Female , Greece , Humans , Male , Middle Aged , Neuropsychological Tests/standards , Neuropsychological Tests/statistics & numerical data , Reference Values , Trail Making Test/standards , Verbal Behavior/physiology , Visual Perception/physiology , Young Adult
8.
Eur Neurol ; 58(2): 96-9, 2007.
Article in English | MEDLINE | ID: mdl-17565222

ABSTRACT

Serum folate and vitamin B12 levels were measured in 67 consecutive Parkinson's disease patients treated either with levodopa + dopa decarboxylase inhibitor (DDC-i) plus catechol-O-methyltransferase inhibitors (COMT-i) or only with levodopa + DDC-i. The data were compared to 67 age-matched controls. Our findings show that levodopa-treated Parkinson's disease patients have low folate (p < 0.0007) and vitamin B12 levels (p < 0.0003). They also demonstrate that the addition of a COMT-i to levodopa + DDC-i treatment causes lower serum vitamin B12 (p < 0.03) and folate levels (p < 0.005) than levodopa + DDC-i treatment alone. We suggest supplementary treatment with vitamin B12 and folic acid in these situations.


Subject(s)
Antiparkinson Agents/pharmacology , Catechols/pharmacology , Folic Acid/blood , Levodopa/pharmacology , Nitriles/pharmacology , Parkinson Disease/blood , Vitamin B 12/blood , Aged , Analysis of Variance , Antiparkinson Agents/therapeutic use , Case-Control Studies , Catechols/therapeutic use , Female , Humans , Immunoassay/methods , Levodopa/therapeutic use , Male , Middle Aged , Nitriles/therapeutic use , Parkinson Disease/drug therapy
9.
Acta Neurol Scand ; 115(1): 67-72, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17156268

ABSTRACT

OBJECTIVES: We evaluated cross-sectionally the associations of depression and anxiety with age, sex, duration of illness, educational level, degree of disability and treatment with interferon-beta in outpatients with relapsing-remitting multiple sclerosis (RRMS) during a clinically stable phase of their illness. MATERIALS AND METHODS: The depression status scored on the Beck Depression Inventory (BDI), the symptoms of anxiety assessed using the State Trait Anxiety Inventory (STAI) and the level of disability measured by the Expanded Disability Status Scale (EDSS) were quantified in 86 consecutive RRMS patients. RESULTS: Linear regression analyses indicated that EDSS was independently (P < 0.001) associated with BDI and STAI and accounted for 15.7% and 18.5% of the variance in BDI and STAI respectively. The former association retained its statistical significance in multiple regression models adjusting for demographic and clinical characteristics. CONCLUSIONS: Disability status is an independent but moderate determinant of depression and anxiety in MS patients.


Subject(s)
Anxiety Disorders/etiology , Depressive Disorder/etiology , Disability Evaluation , Multiple Sclerosis, Relapsing-Remitting/complications , Adult , Cross-Sectional Studies , Educational Status , Female , Humans , Immunologic Factors/therapeutic use , Interferon-beta/therapeutic use , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Risk Factors , Severity of Illness Index , Sex Factors , Time Factors
10.
J Neurol Sci ; 241(1-2): 25-9, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16316662

ABSTRACT

UNLABELLED: Interleukin-15 (IL-15) is a novel proinflammatory cytokine having similar biological activities to IL-2 which is implicated in the pathogenesis of multiple sclerosis. It is produced by activated blood monocytes, macrophages and glial cells. There is little information about the involvement of IL-15 in the development of multiple sclerosis (MS). The objective of our study was to measure IL-15 serum and cerebrospinal fluid (CSF) levels in MS patients and to correlate serum and CSF IL-15 concentrations with clinical parameters of the disease. CSF IL-15/Serum IL-15 ratio (c/s IL-15 ratio) was introduced to assess the origin of elevated IL-15 levels. MATERIALS AND METHODS: We measured serum and CSF IL-15 levels in 52 patients with MS and 36 age and gender matched patients with inflammatory (IND) and non-inflammatory neurological diseases (NIND) studied as control groups. IL-15 levels were correlated with clinical parameters as duration, disability, MRI activity and clinical subtypes of the disease. RESULTS: MS patients were found to have significantly higher serum IL-15 levels compared with IND (p=0.00016) and NIND patients (p=0.00045). Elevated levels of IL-15 were also found in CSF samples from MS patients compared with patients with IND (p=0.00034) and NIND (p=0.0003). Among MS subgroups there were no statistically different IL-15 serum and CSF concentrations. No significant correlation of serum and CSF IL-15 concentrations with MRI activity, disability assessed by EDSS score and duration of the disease were also found. C/S IL-15 ratio was found lower in MS patients compared with IND (p=0.01) and not significantly different compared with NIND patients (p=0.14) suggesting that systemic activation might be the source of high CSF IL-15 levels in MS patients. CONCLUSIONS: Our findings suggest a possible role of IL-15 in the immunopathogenetic mechanisms of MS.


Subject(s)
Interleukin-5/blood , Interleukin-5/cerebrospinal fluid , Multiple Sclerosis/blood , Multiple Sclerosis/cerebrospinal fluid , Adolescent , Adult , Case-Control Studies , Enzyme-Linked Immunosorbent Assay/methods , Female , Humans , Male , Middle Aged , Nervous System Diseases/blood , Nervous System Diseases/cerebrospinal fluid , Statistics, Nonparametric
11.
J Neurooncol ; 75(2): 229-32, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16283448

ABSTRACT

OBJECTIVE: To describe a case of limbic encephalitis which initially presented as viral limbic encephalitis and during the clinical evaluation a renal carcinoma was diagnosed. CASE REPORT: Patient with history of peripheral paresis of right facial nerve, 1 month after symptoms appearance and treatment, developed fever, vomiting, grand mal seizure, decreased level of consciousness, confusion, hallucinations and agitation. The patient initially presented a clinical picture of viral LE. which confirmed by CSF. MRI brain showed areas with pathological intensity signal in the region of limbic system unilateral. During the clinical evaluation a renal carcinoma was discovered and a nephrectomy has been performed. CONCLUSIONS: Although PLE typically presents as a chronic or subacute disease, it may be fulminant and clinically indistinguishable from an acute HSVE. This association pose the problem of a possible relation between this two syndromes and the correct diagnosis is very important, because there are effective treatments.


Subject(s)
Carcinoma, Renal Cell/complications , Encephalitis, Viral/diagnosis , Limbic Encephalitis/pathology , Limbic System/pathology , Paraneoplastic Syndromes, Nervous System/diagnosis , Acute Disease , Acyclovir/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anticonvulsants/therapeutic use , Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/surgery , Cerebrospinal Fluid/microbiology , Diagnosis, Differential , Drug Therapy, Combination , Electroencephalography , Encephalitis, Viral/cerebrospinal fluid , Encephalitis, Viral/drug therapy , Encephalitis, Viral/etiology , Enoxaparin/therapeutic use , Ethambutol/therapeutic use , Follow-Up Studies , Herpesvirus 1, Human/drug effects , Humans , Isoniazid/therapeutic use , Limbic Encephalitis/drug therapy , Limbic Encephalitis/psychology , Magnetic Resonance Imaging , Male , Meningoencephalitis/diagnosis , Meningoencephalitis/drug therapy , Meningoencephalitis/etiology , Methylprednisolone/therapeutic use , Middle Aged , Nephrectomy , Neuropsychological Tests , Paraneoplastic Syndromes, Nervous System/pathology , Phenytoin/therapeutic use , Rifampin/therapeutic use , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , Vancomycin/therapeutic use
12.
Seizure ; 11(7): 442-4, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12237070

ABSTRACT

The EEGs of 13,560 patients have been reviewed in order to determine whether abnormal findings, epileptiform or not, have a hemispheric dominance. We have included outpatients and hospitalized patients as well. Eight hundred and thirty-five EEGs had generalized abnormal findings, and 414 EEGs had lateralized abnormal findings. The EEGs of 322 patients (77.7%) had a left predominance, and those of 92 patients (22.3%) had a right predominance, of abnormal findings. A strong left predominance has been noted for the epileptiform discharges, i.e. 128 (79%) vs. 34 (21%). These results raise the possibility that the left hemisphere may be more vulnerable to nosological processes.


Subject(s)
Brain/physiopathology , Electroencephalography , Epilepsy/physiopathology , Functional Laterality/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Epilepsy/diagnosis , Female , Humans , Male , Middle Aged , Retrospective Studies
13.
Seizure ; 9(8): 580-4, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11162756

ABSTRACT

Sedated sleep and sleep deprivation are commonly used methods to increase the diagnostic yield of the electroencephalogram (EEG), especially in the evaluation of people with epilepsy, but the rate of activation achieved by them is controversial, as is the issue of whether it is sleep itself, or sleep deprivation which is responsible for their alleged efficacy. We retrospectively studied the EEGs of epileptic patients, examined in our laboratory, who, after having undergone an inconclusive initial routine recording, had then been examined with a second recording. This was after either: (1) sleep deprivation with evidence of drowsiness in the recordings, (2) sleep deprivation without drowsiness (indicative of the effect which sleep deprivation per se has in eliciting abnormal patterns), or (3) drug-induced sedation. The activation rates found were (1) 22.5%, (2) 24% (22.6% for sleep deprivation collectively, regardless of the presence or not of subsequent drowsiness) and (3) 27% respectively. Only the sleep deprivation rate was statistically different from the 9.6% increased rate of abnormal patterns elicited by the simple repeating of a second routine recording, while the rate of drug-induced sleep was not. Although, sleep deprivation appeared to be more effective as an activating method of EEG compared with sedated sleep, no conclusions could be drawn about which stage of sleep, wakefulness or drowsiness, is primarily responsible for the method's efficacy.


Subject(s)
Electroencephalography , Epilepsy/diagnosis , Sleep Deprivation/physiopathology , Sleep Stages/physiology , Adolescent , Adult , Aged , Arousal/physiology , Cerebral Cortex/physiopathology , Epilepsy/physiopathology , Evoked Potentials/drug effects , Evoked Potentials/physiology , Female , Humans , Hypnotics and Sedatives , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity
14.
Electromyogr Clin Neurophysiol ; 37(5): 317-20, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9298345

ABSTRACT

Event-related potentials (ERPs) were elicited in 30, non-consecutive, non-demented individuals, complaining of short-term memory disturbances. Fifteen of them had a moderate diffuse cerebral atrophy on their brain CT and the other 15 had a negative brain CT. ERPs were also elicited in 15 age-matched controls with no reported memory disturbances and negative brain CTs. The statistical analysis showed that the group of individuals with cerebral atrophy had a significantly prolonged P300 (P3) latency and a decreased P3 amplitude compared to controls. It is concluded that among persons complaining of short-term memory disturbances, the individuals who show cerebral atrophy, taken as a group, have a P3 latency prolongation and/or low P3 amplitude a finding which reflects an impaired information processing.


Subject(s)
Brain Damage, Chronic/diagnosis , Cognition Disorders/physiopathology , Event-Related Potentials, P300/physiology , Memory, Short-Term/physiology , Tomography, X-Ray Computed , Adult , Aged , Atrophy , Attention/physiology , Brain Damage, Chronic/physiopathology , Brain Mapping/instrumentation , Cerebral Cortex/pathology , Cognition Disorders/diagnosis , Electroencephalography , Humans , Middle Aged , Pitch Discrimination/physiology , Reaction Time/physiology , Reference Values , Signal Processing, Computer-Assisted
15.
Anticancer Res ; 17(3B): 1593-7, 1997.
Article in English | MEDLINE | ID: mdl-9179200

ABSTRACT

In-111 pentetreotide is a new radiolabelled [OctreoScan 111, Mallinckrodt Medical BV, Petten] somatostatin analog with high affinity to somatostatin receptors (SR). introduced for the in vivo imaging of SR positive tissues. In an attempt to evaluate its clinical usefulness for tissue characterization in malignancies without neuroendocrine expression in parallel with histological and radiological examinations, specific scintigraphy was performed on brain (6 cases), thyroid (6 cases) and breast (9 cases) tumors, and in lymphomas (9 cases) and melanomas (6 cases). A dose of 111MBq of In-111 pentetreotide was injected i.v. to each patient and scintimages at 6 and 22 hours (for comparison) p.i. were obtained. The primary lesion of the breast cancer population was imaged in all 9 cases as well as all the palpable axillary nodes in 4 cases. Three women with impalpable axillary lymph nodes scanned negative but had a positive biopsy. Both meningiomas were positive for SR scans: positive results were also obtained for the high grade astrocytoma and the craniopharyngioma: Two out of 6 patients with papillary thyroid cancer showed a marked radiotracer accumulation. Scintigraphy in all 5 lymphomas was positive for SR but did not detect the Tc-99m sulphur microcolloid [Lymphoscint, Solco, Basel, Suitzerland] imaged lymph nodes in 5 melanomectomized patients. When judging the imaging results of these non-neuroendocrine malignancies definite conclusions should not be drawn since the number of studied cases polymorph, was small for every cancer histotype; nevertheless SR scintigraphy does not seem to be reliable for tumor staging in non-neuroendocrine malignancies, but is more suitable for a tissue characterization and monitoring changes of SR expression during and after therapy.


Subject(s)
Brain Neoplasms/diagnostic imaging , Breast Neoplasms/diagnostic imaging , Lymphoma/diagnostic imaging , Melanoma/diagnostic imaging , Receptors, Somatostatin/analysis , Skin Neoplasms/diagnostic imaging , Somatostatin/analogs & derivatives , Thyroid Neoplasms/diagnostic imaging , Adolescent , Adult , Brain Neoplasms/pathology , Breast Neoplasms/pathology , Female , Humans , Indium Radioisotopes , Lymphatic Metastasis , Lymphoma/pathology , Magnetic Resonance Imaging , Male , Melanoma/pathology , Skin Neoplasms/pathology , Thyroid Neoplasms/pathology , Tomography, Emission-Computed
16.
Anticancer Res ; 17(3B): 1699-704, 1997.
Article in English | MEDLINE | ID: mdl-9179222

ABSTRACT

Prostate carcinoma is the most commonly associated with osseous metastases malignancy in males. The lesions, being usually of a mixed sclerotic/lytic variety and less often of the pure sclerotic type, need to be treated by a bone seeking radioactive element with an as low as possible radiobiological burden on the surrounding (peritumoral) tissues. Rhenium-186-HEDP was used to treat these osseous metastatic lesions due to its bone seeking kinetics attractive radiochemical properties. Of a total of 16 prostate cancer patients. 3 experiment loss of pain, 8 experienced obvious and 2 some improvement. No change was observed in 3 patients. Ten patients manifested a flare syndrome increasing pain approximately 2 to 6 days, after Re-186-HEDP i.v. application. Six patients showed a definite and 9 a slight decrease in platelet levels and absolute number of polymorphonuclear white blood cells, up to fourth week following treatment. One patient underwent a whole blood transfusion and in 2 peripheral neuropathy was observed lasting about 9 to 12 days. Re-186-HEDP appears to be a promising new metal ion complex for the palliation of painful bone metastases in prostate cancer. Compared to Sr-89 therapy, it shows a longer analgetic efficacy and has the advantage of emitting gamma rays, a fact which facilitates dosimetric calculations.


Subject(s)
Bone Neoplasms/radiotherapy , Bone Neoplasms/secondary , Etidronic Acid/therapeutic use , Prostatic Neoplasms/radiotherapy , Rhenium/therapeutic use , Aged , Aged, 80 and over , Bone Neoplasms/diagnostic imaging , Bone Neoplasms/physiopathology , Humans , Male , Organometallic Compounds , Pain Measurement , Pain, Intractable , Palliative Care , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/pathology , Prostatic Neoplasms/physiopathology , Radioisotopes , Radionuclide Imaging , Technetium Tc 99m Medronate
17.
Hybridoma ; 16(1): 133-7, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9085140

ABSTRACT

Somatostatin receptors (SR) are surface markers characterizing not only APUDomas associated with neuroendocrine identities but also malignancies without neuroendocrine expression. Recently, the somatostatin analog pentetreotide was labeled with In-111 (OctreoScan 111, Mallinckrodt Medical BV, Petten, Holland) and introduced for the in vivo visualization in man of SR-positive tissues. In the present report, SR-specific scintigraphy is evaluated as a clinical tool for tissue characterization in correlation with histological and radiological examinations. Scintigraphy was focused and performed in cancer types without neuroendocrine tissue expression such as brain (n = 6) and breast tumors (n = 9) and lymphomas (n = 5). Scintigraphy was performed for comparison at 6 and 22 h after i.v. application of 111 MBq (3 mCi) of In-111-Pentetreotide. In the breast cancer group, the primary tumor was visualized in all 9 women as well as in all 4 cases with palpable axillary lymph nodes. Three women with a negative axillary node scan and impalpable nodes had positive biopsy. In two cases, mediastinal lymph node involvement was observed. So far the role of SR-positive breast cancer (BC) scans remains unknown. It is tempting to speculate that in resected women who are histologically and scintigraphically SR positive, it might be of value in the early detection of symptom-free recurrences. High densities of SR were present within both meningiomas, the high-grade astrocytoma and the craniopharyngioma. Differentiation of low- and high-grade astrocytomas could not be successfully achieved because both grades showed intense radioactivity uptake, even though high-grade tumors lack SR. The latter might be due to the damaged blood-brain barrier and the poor radioactivity washout observed in high-grade astrocytomas. All five lymphomas could be detected due to the presence of activated lymphocytes and macrophages that express SR at a sufficient density. In conclusion, SR scintigraphy in non-neuroendocrine malignancies does not seem to be reliable for an initial tumor staging but rather more suitable for a tissue characterization and extremely useful for monitoring changes of SR expression after treatment.


Subject(s)
Indium Radioisotopes , Neoplasms/diagnostic imaging , Receptors, Somatostatin/metabolism , Somatostatin/analogs & derivatives , Adolescent , Adult , Aged , Brain Neoplasms/diagnostic imaging , Breast Neoplasms/diagnostic imaging , Carcinoma, Neuroendocrine/diagnostic imaging , Diagnosis, Differential , Female , Humans , Indium Radioisotopes/metabolism , Lung Neoplasms/diagnostic imaging , Lymphoma/diagnostic imaging , Male , Middle Aged , Radionuclide Imaging , Somatostatin/metabolism
18.
Acta Neurol Scand ; 86(5): 462-5, 1992 Nov.
Article in English | MEDLINE | ID: mdl-1481627

ABSTRACT

Auditory event-related potentials (AERP) were elicited in 68 epileptic patients and 30 age-matched controls. Epileptic patients had significantly prolonged N2 and P300 (P3) latencies compared with controls. Seven patients were above the range of 3 standard deviations from the control mean values. Amongst epileptics, patients with temporal lobe epilepsy had significantly prolonged P3 latencies compared to patients with idiopathic generalized epilepsy. Patients with abnormal EEGs had significantly prolonged P3 latencies compared to those with normal EEGs. Patients on anticonvulsant monotherapy had shorter P3 latencies, compared to patients taking a combination of two or more anticonvulsants. Patients on shorter duration of treatment had less prolonged P3 latencies compared to those on longer anticonvulsant treatment.


Subject(s)
Anticonvulsants/therapeutic use , Cognition Disorders/physiopathology , Electroencephalography/drug effects , Epilepsies, Partial/physiopathology , Epilepsy, Generalized/physiopathology , Evoked Potentials, Auditory/physiology , Reaction Time/physiology , Adolescent , Adult , Cerebral Cortex/drug effects , Cerebral Cortex/physiopathology , Epilepsies, Partial/drug therapy , Epilepsy, Frontal Lobe/drug therapy , Epilepsy, Frontal Lobe/physiopathology , Epilepsy, Generalized/drug therapy , Epilepsy, Temporal Lobe/drug therapy , Epilepsy, Temporal Lobe/physiopathology , Evoked Potentials, Auditory/drug effects , Female , Humans , Male , Middle Aged , Reaction Time/drug effects
19.
Electromyogr Clin Neurophysiol ; 32(10-11): 531-5, 1992.
Article in English | MEDLINE | ID: mdl-1446585

ABSTRACT

Auditory Event-Related Potentials (AERP) were elicited in 25 beta-thalassemic patients, three days before and three days after a blood transfusion. The amplitude, latency and topographic distribution of P300 (P3) as well as N1, P2, N2 components were measured for the two assessment times. No significant differences in either amplitude, latency or topography were observed between the two situations, but thalassemic patients had significantly prolonged P3 latencies comparing to controls though none of them exceeded 3 standard deviations of the control mean values. Regarding P3 topography, 10 out of 25 patients showed a right centroparietal distribution area. It is concluded that information processing, as far as it is reflected in AERP components is impaired in thalassemic patients and blood transfusion have no significant influence in cognitive functions.


Subject(s)
Brain/physiopathology , Cognition/physiology , Evoked Potentials, Auditory/physiology , beta-Thalassemia/physiopathology , Adolescent , Adult , Brain Mapping , Electroencephalography , Female , Humans , Male , Reaction Time/physiology
20.
Acta Neurol Scand ; 85(1): 10-3, 1992 Jan.
Article in English | MEDLINE | ID: mdl-1546528

ABSTRACT

Auditory event-related potentials (AERP) were elicited in 47 patients with relapsing-remitting (RR) multiple sclerosis (MS) and 24 age-matched controls. MS patients had significantly prolonged N2 and P3 latencies as well as low P3 amplitude compared with controls. Seven of them exceeded 3 standard deviations from the control mean values. The observed N2 and P3 alterations are associated with the patients' disability status as it is defined by the Kurtzke expanded disability status scale (EDSS), but are not related to the duration of the disease. A possible cognitive decline as reflected in the observed AERP components alterations in MS patients is subsequently discussed.


Subject(s)
Arousal/physiology , Attention/physiology , Brain Damage, Chronic/physiopathology , Electroencephalography/instrumentation , Multiple Sclerosis/physiopathology , Signal Processing, Computer-Assisted/instrumentation , Adult , Brain Damage, Chronic/diagnosis , Brain Mapping/instrumentation , Cerebral Cortex/physiopathology , Evoked Potentials, Auditory/physiology , Female , Humans , Male , Multiple Sclerosis/diagnosis , Pitch Discrimination/physiology , Reaction Time/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...